Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques

J Am Chem Soc. 2004 Dec 22;126(50):16316-7. doi: 10.1021/ja044911a.

Abstract

A new contrast agent for MRI based on recombinant HDL-like nanoparticles has been prepared. It shows a great potential as a contrast agent for atherosclerotic plaques in a relative short time (24 h post-injection) as it is selective for the plaques and is an endogenous molecule. It also can distinguish between different types of plaques as the enhancement obtained is different, depending on plaque composition.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Arteriosclerosis / diagnosis*
  • Arteriosclerosis / metabolism
  • Arteriosclerosis / pathology
  • Contrast Media* / chemistry
  • Contrast Media* / pharmacology
  • Fluorescent Dyes
  • Gadolinium DTPA / chemistry
  • Gadolinium DTPA / pharmacokinetics
  • Humans
  • Indoles
  • Lipoproteins, HDL* / chemistry
  • Lipoproteins, HDL* / pharmacokinetics
  • Magnetic Resonance Imaging / methods*
  • Microscopy, Confocal
  • Microscopy, Fluorescence
  • Nanostructures / chemistry*
  • Phosphatidylethanolamines / chemistry
  • Phosphatidylethanolamines / pharmacokinetics
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / pharmacokinetics

Substances

  • Contrast Media
  • Fluorescent Dyes
  • Indoles
  • Lipoproteins, HDL
  • Phosphatidylethanolamines
  • Recombinant Proteins
  • DAPI
  • Gadolinium DTPA
  • 1,2-dimyristoylphosphatidylethanolamine